Navigation Links
Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
Date:2/7/2008

BEIJING, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that Enze Jiashi Pharmaceutical, Ltd. ("Enze"), a wholly owned subsidiary of Lotus, has implemented cost saving strategies, which it expects will reduce its production costs by approximately 50%.

The environmentally-friendly strategies are expected to significantly lower electricity and water usage of the production facility. The Company intends to spend $0.8 million to apply new technology to the facility's boiler systems, vapour systems and cooling drainage systems. These changes are expected to significantly reduce the cost of steam, heating and water used in the manufacturing process by 50%, 60% and 50%, respectively.

"As a result of implementing these strategies, Enze is expected to lower annual manufacturing expenses by RMB 8 to 10 million (approximately $US 1 to 1.4 million). This will not only improve our margins but has the added benefit of reducing the amount of energy used at the facility, which is good for the environment," said Dr. Zhongyi Liu, Chairman, CEO and President of Lotus Pharmaceuticals, Inc.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Liangfang Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd. ("Enze"), two Chinese pharmaceutical companies located in Beijing. Liangfang and Enze form a large comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. Together, they possess some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Liangfang and/or Enze (together, "Lotus East"), and a number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters, warehouse of 1,000 square meters and operates ten retail pharmacies in the Beijing area. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines. For more information, visit http://www.LotusEast.com.

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward- looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
2. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
3. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
4. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
5. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
6. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
7. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
8. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
9. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
10. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils ... HCCA’s 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... medical chart types with a comprehensive set of features including built-in workflow, interactive ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Wounded Woman ... “Wounded Woman Be Ye Healed-Passing On A Legacy” is the creation of published author, ... founder of Comfortbearers grief ministry. She has been happily married to her husband, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To Atheist ... To Atheist Manifesto” is the creation of published author Richard Hostetter, a former ... years. He holds graduate degrees from Kent State University and the University of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... today announced the publication of “Profiling protein expression in circulating tumor cells using ... publication describes the use of the Vortex technology to capture CTCs ...
(Date:3/22/2017)... ... March 23, 2017 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... Convention, currently taking place at the Suntec Singapore International Exhibition & Convention Centre, ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Insight 2022" drug pipelines to their offering. ... Global Immune ... gives comprehensive insight on clinical and non-clinical aspects involved in ... main streamline drugs in the immunotherapy treatment. Report helps to ...
(Date:3/22/2017)... Mar 22, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their ... The ... of around 7.1% over the next decade to reach approximately $129.81 ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 22, 2017  Applied BioMath ( ... to drug research and development, today announced the ... QSP Day 2017 is a day full of ... systems pharmacology (QSP) community. The focus is to ... de-risking and accelerating drug research and development. ...
Breaking Medicine Technology: